Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa study of PM1003 in advanced malignant solid tumors
ChiCTR2100052887Phase 2Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Sep 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of PM1003 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), endometrial cancer (EC) and 4 more (7 arms), sponsored by Shanghai East Hospital. Primary endpoints: Occurrence of dose-limiting toxicity, Objective response rate and 2 more. Started Sep 2021; status: recruiting.
02
Drugs
PM1003
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)endometrial cancer (EC)Cervical Cancer (CC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2100052887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052887.